| Methods | n = 36 Allocation concealment: not described Baseline similarity: not described Blinding: caregivers not blinded (no placebo) Cointerventions: not described Withdrawals: none Losses to follow‐up: none |
|
| Participants | Patients with ALI/ARDS (not described) | |
| Interventions | Intratracheal porcine surfactant (HL10) with 100‐200 mg/kg of phospholipids, up to 4 doses, or standard therapy | |
| Outcomes | 28 day mortality: RR 0.21 (95% CI 0.05 to 0.91) Ventilator free days to day 28: MD 0.80 (95% CI ‐6.33 to 7.93) |
|
| Notes | Published only as abstract | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.